25
total announcements
CONCORDBIO.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 14 Oct 2026
Market Cap
₹14,329 Cr
P/E (TTM)
46.9
P/E (Forward)
32.2
EPS (TTM)
₹29.18
52W Low
₹987.00
52W High
₹1,615.00
Dividend Yield
0.56%
Beta
0.37
Price / Book
7.1
Debt / Equity
0.1
Revenue (TTM)
₹1,108 Cr
Gross Margin
64.56%
Operating Margin
24.96%
Concord Biotech Limited
Concord Biotech Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and listing of securities on stock exchanges.
Concord Biotech Limited
Concord Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Concord Biotech Limited
Concord Biotech Limited has completed the inspection by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda at its Unit-II formulation facility.
CONCORDBIO
Concord Biotech Limited (CONCORDBIO) has announced an investment agreement with FSGE Renewable Power Private Limited, categorised under an acquisition intimation. The company will invest in a Wind Solar Hybrid Power Project designed with a wind capacity of approximately 6.3 MW AC. This strategic move, which follows a previous intimation, marks CONCORDBIO's entry into renewable energy generation. For investors, this signifies the company's commitment to sustainable practices and could lead to long-term operational efficiencies.
Concord Biotech Limited
Concord Biotech Limited has informed the exchanges about its upcoming schedule for an Analyst/Institutional Investor meet. The company's officials will participate in a Non-Deal Roadshow (NDR) to engage with investors. This outreach allows the company to interact directly with the investment community, sharing insights into its operations and strategy. While no specific financial figures or immediate decisions were disclosed, such events help foster transparency and investor relations.